Lack of correlation of stem cell markers in breast cancer stem cells

Y. Liu; R. Nenutil; M. V. Appleyard; K. Murray; M. Boylan; A. M. Thompson; P. J. Coates

doi:10.1038/bjc.2014.105

Lack of correlation of stem cell markers in breast cancer stem cells

Y. Liu
, R. Nenutil
, M. V. Appleyard
, K. Murray
, M. Boylan
, A. M. Thompson
, P. J. Coates

Research output: Contribution to journal › Article › peer-review

86 Citations (Scopus)

287 Downloads (Pure)

Abstract

Background:Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties. Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic response is controversial.Methods:We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to doxorubicin, docetaxol and radiotherapy.Results:CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo, cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface. Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate.Conclusions:Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will require identification of specific markers or panels for the individual cancer.
British Journal of Cancer advance online publication, 27 February 2014; doi:10.1038/bjc.2014.105 www.bjcancer.com.

Original language	English
Pages (from-to)	2063-2071
Number of pages	9
Journal	British Journal of Cancer
Volume	110
Issue number	8
DOIs	https://doi.org/10.1038/bjc.2014.105
Publication status	Published - 15 Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/bjc.2014.105

Publisher final version
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. NonCommercial — You may not use the material for commercial purposes. ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
Final published version, 1.82 MBLicence: CC BY-NC-SA

http://www.nature.com/bjc/index.html

Cite this

@article{4022a64a19a742309858f24eb862df80,

title = "Lack of correlation of stem cell markers in breast cancer stem cells",

abstract = "Background:Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties. Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic response is controversial.Methods:We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to doxorubicin, docetaxol and radiotherapy.Results:CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo, cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface. Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate.Conclusions:Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will require identification of specific markers or panels for the individual cancer. British Journal of Cancer advance online publication, 27 February 2014; doi:10.1038/bjc.2014.105 www.bjcancer.com.",

author = "Y. Liu and R. Nenutil and Appleyard, \{M. V.\} and K. Murray and M. Boylan and Thompson, \{A. M.\} and Coates, \{P. J.\}",

year = "2014",

month = apr,

day = "15",

doi = "10.1038/bjc.2014.105",

language = "English",

volume = "110",

pages = "2063--2071",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "8",

}

TY - JOUR

T1 - Lack of correlation of stem cell markers in breast cancer stem cells

AU - Liu, Y.

AU - Nenutil, R.

AU - Appleyard, M. V.

AU - Murray, K.

AU - Boylan, M.

AU - Thompson, A. M.

AU - Coates, P. J.

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Background:Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties. Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic response is controversial.Methods:We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to doxorubicin, docetaxol and radiotherapy.Results:CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo, cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface. Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate.Conclusions:Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will require identification of specific markers or panels for the individual cancer. British Journal of Cancer advance online publication, 27 February 2014; doi:10.1038/bjc.2014.105 www.bjcancer.com.

AB - Background:Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties. Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic response is controversial.Methods:We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to doxorubicin, docetaxol and radiotherapy.Results:CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo, cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface. Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate.Conclusions:Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will require identification of specific markers or panels for the individual cancer. British Journal of Cancer advance online publication, 27 February 2014; doi:10.1038/bjc.2014.105 www.bjcancer.com.

U2 - 10.1038/bjc.2014.105

DO - 10.1038/bjc.2014.105

M3 - Article

C2 - 24577057

SN - 0007-0920

VL - 110

SP - 2063

EP - 2071

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 8

ER -

Lack of correlation of stem cell markers in breast cancer stem cells

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this